Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by archmanon Aug 03, 2018 4:31pm
164 Views
Post# 28412717

RE:RE:RE:Thx to danceswithhorses...for the post

RE:RE:RE:Thx to danceswithhorses...for the postI agree that setting up a nasdaq listing now makes perfect sense so that RVXCF is able to tap the capital markets for the next phase of operations, if that is the preferred route (would have been better a couple of years ago, in my humble opinion, but maybe difficult from a cash perspective).  Management is absolutely correct in working on all fronts under the asumption that BOM will be a complete success.

I just get nervous when I see a poster insinuate that management must "know" something about the outcome of the trial, because they do not.  

If BOM is a success(which I think it will be), then the Assure failure would have been a blessing in disguise for those of us who were able to load up a sh*tload more shares in the interim period at much lower prices than had it succeeded back then

GLTA.
Bullboard Posts